Abstracts Archive - Page 62 of 2607 - ACR Meeting Abstracts

Abstract Number: 0252 • ACR Convergence 2025
Capillaroscopic Signatures in Autoimmune Rheumatic Diseases: Unveiling Patterns in Systemic Sclerosis, Polyautoimmunity, and PAH
María Paula Carrillo¹, Juan Esteban Bedoya-Loaiza¹, Claudia Ibáñez-Antequera¹, Laura Gallego¹, Alejandro Escobar¹, Adriana Rojas-Villarraga² and Jairo Cajamarca-Baron³, ¹Fundacion universitaria de ciencias de la salud, Bogota, Distrito Capital de Bogota, Colombia, ²Fundacion Universitaria de Ciencias de la salud, Bogotá, Distrito Capital de Bogota, Colombia, ³Fundacion universitaria de ciencia de la Salud, Bogota, Distrito Capital de Bogota, Colombia
Background/Purpose: Nailfold capillaroscopy is a fundamental tool in rheumatology for assessing capillary morphology, allowing the differentiation between primary and secondary Raynaud’s phenomenon, identifying risks associated…
Abstract Number: 0226 • ACR Convergence 2025
Integration of the 5Ms of Geriatrics in a Novel Geri-Rheumatology Clinic
Justin Levinson¹ and Christie Bartels², ¹University of Wisconsin- Madison, Madison, WI, ²University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Geriatric integrative care models, such as the Perioperative Optimization of Senior Health (POSH) initiative, have shown improved outcomes (PMID: 29299599), yet there remains limited…
Abstract Number: 0029 • ACR Convergence 2025
A Novel B Cell Subpopulation Characteristic of IgA Vasculitis Identified by Single-Cell RNA Sequencing
Joao Carlos Batista-Liz¹, María Sebastián Mora-Gil², Evan Troendle³, Oisin Cappa³, Maite Leonardo⁴, Ana Peñalba⁴, Luis mARTIN pENAGOS⁵, Ligia Gabrie-Rodriguez⁶, Rafael Gálvez Sánchez⁶, Jose Luis Callejas⁷, Belen Sevilla⁸, Diego de Argila⁹, Esther Vicente-Rabaneda⁹, Santos Castañeda¹⁰, David Simpson³, Ricardo Blanco¹¹, Verónica Pulito Cueto¹ and Raquel Lopez Mejias¹, ¹IDIVAL, Santander, Spain, ²Immunopathology Group, IDIVAL, Santander, Spain, ³Queens University, Wellcome-Wolfson Institute for Experimental Medicine, Belfast, United Kingdom, ⁴Division of Pediatrics, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁵Immunopathology Group, IDIVAL and Division of Nephrology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁶Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ⁷Department of Internal Medicine, Hospital San Cecilio, Granada, Spain, ⁸Division of Pediatrics, Hospital Universitario San Cecilio, Granada, Spain, ⁹Hospital Universitario de la Princesa, Madrid, Spain, ¹⁰Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, ¹¹Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain
Background/Purpose: IgA vasculitis (IgAV) is a systemic small-vessel vasculitis characterized by immune complex deposition containing aberrantly glycosylated IgA1. While its clinical manifestations are well defined…
Abstract Number: 0282 • ACR Convergence 2025
Clinical Meaningfulness and Improvement Thresholds of Myositis Core Set Measures: Association with Patient-Reported Outcomes
Shiri Keret¹, Raisa Lomanto Silva², Irada Choudhuri³, Eugenia Gkiaouraki³, Tanya Chandra³, Nantakarn Pongtarakulpanit³, Shreya Sriram³, Niladri Bhowmick³, Vaidehi Kothari³, Kaushik Sreerama Reddy³, Eaman Alhassan⁴, Anushka Aggarwal⁵, Maha Almackenzie⁶, Siamak Moghadam-Kia⁴, Dana Ascherman⁷, Chester V. Oddis⁷ and Rohit Aggarwal⁸, ¹Bnai Zion Medical Center, Atlit, Israel, ²Massachusetts General Hospital, Boston, MA, ³University of Pittsburgh Medical Center, Pittsburgh, ⁴University of Pittsburgh Medical Center, Pittsburgh, PA, ⁵Indraprastha Apollo Hospital, New Delhi, India, ⁶Medical Cities of the Ministry of the Interior, Riyadh, Saudi Arabia, ⁷University of Pittsburgh, Pittsburgh, PA, ⁸University of Pittsburgh, Rheumatology and Clinical Immunology, Pittsburgh, United States of America, Pittsburgh, PA
Background/Purpose: The six myositis core set measures (CSMs) are widely utilized to assess disease activity in idiopathic inflammatory myopathies (IIM). However, their association with how…
Abstract Number: 0337 • ACR Convergence 2025
Bridging the Bone Gap: A Quality Improvement Project on Osteoporosis Screening Practices in a Teaching Institution
Aakanksha Pitliya¹, Alexandra Georgiana Boc², Hema Latha Anam², Richard Oletsky², Dipabali Chaudhuri² and Rajesh Thirumaran², ¹Mercy Catholic Medical Center, Darby, PA, Clifton Heights, PA, ²Mercy Catholic Medical Center, Darby, PA
Background/Purpose: Osteoporosis remains underdiagnosed despite clear guidelines. As primary care physicians and trainees are key to preventive care, this quality improvement (QI) project aimed to…
Abstract Number: 0301 • ACR Convergence 2025
Novel HMGCS1 Deficiency Expands Proinflammatory Monocytes and Cytotoxic Populations with Increased Cytokine Release
Sabrina Helmold Hait¹, Mary Maclean², Cindy Phung³, Gustaf wigerblad⁴, Iago Pinal Fernandez⁴, Carl Esperanzate⁵, hongying Wang⁵, Andrew Mammen⁶, willian Gahl⁵, Daniel L. Kastner⁷, Stefania Dell'orso⁴, Danica Novacic⁵, massimo Gadina⁴ and Ivona Aksentijevich⁸, ¹NIAMS/NIH, Bethesda, MD, ²NIH-NIAMS, Rockville, MD, ³National Institute of Arthritis, Musculoskeletal, and Skin Diseases (NIAMS), Bethesda, MD, ⁴National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ⁵National Human Genome research Institute (NHGRI), National Institutes of Health (NIH), Bethesda, MD, ⁶NIH, Bethesda, MD, ⁷National Human Genome research Institute (NHGRI), National Institutes of Health (NIH), Bethesda, ⁸¹⁰⁰, Bethesda, MD
Background/Purpose: The mevalonate (MVK) pathway synthesizes isoprenoids that mediate post-translational protein modifications via prenylation. Deficient protein prenylation due to decreased mevalonate kinase (MK) activity leads…
Abstract Number: 0305 • ACR Convergence 2025
From Movement to Meaning: Exploring Physical Function in IBM with Actigraphy
Vaidehi Kothari¹, Eaman Alhassan², Kevin Renz Ambrocio¹, Bonny Rockette-Wagner³, Chester V. Oddis¹, Kendrea (Focht) Garand¹ and Rohit Aggarwal⁴, ¹University of Pittsburgh, Pittsburgh, PA, ²University of Pittsburgh Medical Center, Pittsburgh, PA, ³University of Pittsburgh, PITTSBURGH, ⁴University of Pittsburgh, Rheumatology and Clinical Immunology, Pittsburgh, United States of America, Pittsburgh, PA
Background/Purpose: Inclusion body myositis (IBM) is a progressive and severe inflammatory muscle disease that primarily affects adults over 50 years of age. It presents with…
Abstract Number: 0272 • ACR Convergence 2025
Ocular Involvement in Behçet’s Disease: Comparative Study of Two Classification Criteria in Clinical Practice
Rafael Gálvez Sánchez¹, José Luis Martín-Varillas², Lara Sánchez Bilbao³, Ivan Ferraz Amaro⁴, Elena Aurrecoechea⁵ and Ricardo Blanco³, ¹Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ²Rheumatology Division, Hospital de Laredo. IDIVAL, Immunopathology Group. Santander, Spain., Laredo, Spain, ³Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain, ⁴Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ⁵Hospital Sierrallana, CANTABRIA, Spain
Background/Purpose: Ocular involvement is a potential severe complication of Behçet’s Disease (BD). The traditional classification, by the International Study Group (ISG, 1990) requires the mandatory…
Abstract Number: 0322 • ACR Convergence 2025
Metabolites Reflective of the Gut Microbiome Relate to Future Incident Knee Osteoarthritis: Data from the Osteoarthritis Initiative
Jeffrey Driban¹, Shike Xu², Timothy McAlindon³, John Haran⁴, Julieann Patarini⁴ and Bing Lu⁵, ¹University of Massachusetts Chan Medical School, Marlborough, NH, ²University of Connecticut Health Center, Farmington, CT, ³UMass Chan School of Medicine, Arlington, MA, ⁴UMass Chan Medical School, Worcester, MA, ⁵UConn Health Center, Newton, MA

Background/Purpose: Numerous cross-sectional and animal studies have linked an altered gut microbiome to osteoarthritis (OA). Human studies are needed to explore the association between the…
Abstract Number: 0288 • ACR Convergence 2025
Predictors and Characteristics of Objective Flares in Adult Dermatomyositis
Didem Saygin¹, York Wang², Kathryn C. Fitzgerald³, Jemima Albayda⁴, Julie Paik⁵, Eleni Tiniakou⁶, Brittany L Adler², Andrew Mammen⁷, Lisa Christopher-Stine⁴ and Chris Mecoli², ¹Rush University Medical Center, Chicago, IL, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, ⁴Johns Hopkins University, Baltimore, MD, ⁵Johns Hopkins Rheumatology, Baltimore, MD, ⁶UT Health Science Houston, Houston, TX, ⁷NIH, Bethesda, MD
Background/Purpose: Dermatomyositis (DM) is a chronic systemic autoimmune disease with a heterogenous clinical course. Flares often lead to increased morbidity, health care utilization, and reduced…
Abstract Number: 0011 • ACR Convergence 2025
KT502, a novel CD19-directed TCE (T-cell engager), leads to rapid and deep B-cell depletion with low cytokine release
Min Bao, John Wang, Jay Zhao and Weihao Xu, Kali Therapeutics, San Mateo, CA
Background/Purpose: Chimeric antigen receptor T-cell (CAR-T) therapies targeting CD19 have shown unprecedented effects in treatment-resistant autoimmune diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis…
Abstract Number: 0237 • ACR Convergence 2025
Monogenic autoinflammatory diseases and undefined autoinflammatory syndrome in Western Mediterranean adults: clinical, genetic, and therapeutic insights
Alba Maria Torrat Noves¹, José Ivorra Cortes², Alejandro Jose Mateo Vendrell², ELENA GRAU GARCIA³, Pablo Muñoz Martinez², Laura Mas Sanchez⁴, Daniel Ramos Castro⁵, Iago Alcántara Álvarez⁶, Belen Villanueva Manes⁷, Andres perez Hurtado², Miguel Simeo Vinaixa², inmaculada Calvo Penades⁸, Berta López Montesinos⁸, Lucia Lacruz-perez⁸ and José Andrés Román Ivorra⁹, ¹Hospital Universitari i Politècnic La Fe de Valencia, Valencia, Spain, ²Rheumatology Department. HUP La Fe, Valencia, Spain, ³HUP La Fe, Valencia, Comunidad Valenciana, Spain, ⁴Hospital Universitari i Politecnic La Fe, València, Spain, ⁵Hospital Universitari i Politecnic La Fe, Valencia, Spain, ⁶Hospital Universitari i Politénic La Fe, València, Spain, ⁷Hospital La Fe, València, Spain, ⁸Pediatric Rheumatology Department. HUP La Fe, Valencia, Spain, ⁹Hospital Universitari i Politècnic La Fe, Valencia, Spain
Background/Purpose: Monogenic autoinflammatory diseases are rare innate immunity disorders characterized by recurrent episodes of fever and systemic inflammation. They are most often described in childhood,…
Abstract Number: 0270 • ACR Convergence 2025
Diagnostic Challenge of IgG4-related Disease: Comparison Between ACR/EULAR, Umehara, and Okazaki Criteria
Rafael Gálvez Sánchez¹, Ivan Ferraz Amaro², Fernando Lopez Gutierrez³, Javier Loricera⁴, Pablo Martínez Calabuig⁵, Jorge Juan Fragío Gil⁶, Roxana González Mazarí⁷, Cristina Hormigos Martín⁸, DALIFER FREITES⁹, Maria Rodríguez Laguna⁸, Patricia Moya Alvarado¹⁰, Marta López I Gómez¹¹, Hector Corominas Macia¹⁰, Maite Silva Díaz¹², Guillermo González Arribas¹², Angel García Aparicio¹³, Judit Font-Urgelles¹⁴, Ivette Casafont Solé¹⁵, Elisabet Castaneda¹⁶, Carolina Merino Argumánez¹⁷, Raquel Zas Vaamonde¹⁸, Juan Molina Collada¹⁹, Sergio Rodríguez Montero²⁰, Rafael Melero Gonzalez²¹, Eva Galíndez Agirregoikoa²², Andrea Hernández²³, Lucia Pantoja Zarza²⁴, Ignacio Braña Abascal²⁵, Vega Jovaní²⁶, Elia Valls Pascual²⁷, Natalia Mena Vázquez²⁸, ADELA MARIA GALLEGO FLORES²⁹, Noelia Cabaleiro Raña³⁰, Raúl Veroz González³¹, Mariano Andrés³², Santos Castañeda Sainz³³ and Ricardo Blanco³⁴, ¹Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ²Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ³Hospital Universitario Marqués de Valdecilla, Immunopathology Group -IDIVAL, Reumatología, Santander, Santander, Spain, ⁴Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ⁵Hospital General Universitario de Valencia, Spain/ Uversidad Catolica de Valencia San Vicente Martir, Valencia, Spain, Ontinyent, Spain, ⁶Hospital General Universitario, Valencia, Spain, ⁷Hospital General Universitario de Valencia, Reumatología, Valencia, Valencia, Spain, ⁸Hospital Clínico San Carlos, Reumatología, Madrid, Madrid, Spain, ⁹Rheumatology Service, San Carlos Clinical Hospital, Madrid, Madrid, Spain, ¹⁰Hospital de Sant Pau, Reumatología, Barcelona, Barcelona, Spain, ¹¹Hospital Universitario de Araba, Reumatología, Vitoria,, Vitoria, Spain, ¹²Complejo Hospitalario Universitario de A Coruña, Reumatología, A Coruña, Spain, ¹³Hospital Universitario de Toledo, Reumatología, Toledo, Toledo, Spain, ¹⁴Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ¹⁵Hospital German Trias i Pujol, Reumatología, Badalona, Badalona, Spain, ¹⁶Hospital Universitario Infanta Sofía, Reumatología, Madrid, Madrid, Spain, ¹⁷Hospital Universitario Puerta del Hierro, Reumatología, Madrid, Madrid, Spain, ¹⁸Hospital Universitario ¹² de Octubre, Reumatología, Madrid, Madrid, Spain, ¹⁹Hospital General Universitario Gregorio Marañón, Reumatología, Madrid, Madrid, Spain, ²⁰Hospital Universitario de Valme, Reumatología, Sevilla, Sevilla, Spain, ²¹Hospital Alvaro Cunqueiro, Reumatología, Vigo, Vigo, Spain, ²²BASURTO UNIVERSITY HOSPITAL, BILBAO, Spain, ²³Hospital Universitario de Gran Canaria Dr Negrin, Reumatología, Palmas de Gran Canaria, Gran Canaria, Spain, ²⁴Hospital General de Segovia, Reumatología, Segovia, Segovia, Spain, ²⁵Hospital Universitario Central de Asturias, Reumatología, Oviedo, Oviedo, Spain, ²⁶Hospital General Universitario de Alicante, Reumatología, Alicante, Alicante, Comunidad Valenciana, Spain, ²⁷Hospital General de Valencia, Reumatología, Valencia, Valencia, Spain, ²⁸Hospital Regional Universitario de Málaga, Reumatología, Málaga, Malaga, Spain, ²⁹Complejo Hospitalario don Benito Villanueva, Reumatología, Badajoz, Badajoz, Extremadura, Spain, ³⁰Hospital Universitario Montecelo, Reumatología, Pontevedra, Pontevedra, Spain, ³¹Hospital de Mérida, Reumatología, Mérida, Mérida, Spain, ³²Hospital General Universitario de Alicante, Reumatología, Alicante, Alicante, Spain, ³³Hospital Universitario La Princesa, Reumatología, Madrid Grupo de cooperación nacional de enfermedad relacionada con IgG⁴: Blanca García Magallón (Hospital Universitario Puerta del Hierro), Maite Odriozola Gil (Hospital Universitario de Valme), Cristina Arciniega (Hospital de Mérida), Maria Lourdes Mateo Soria (Hospital German Trias i Pujol), Santiago Muñoz (Hospital Universitario Infanta Sofía), Iñigo Jesús Rua Figueroa, (Hospital Universitario de Gran Canaria Dr Negrin), Sabela Fernández Aguado, (Hospital de Montecelo)., Madrid, Spain, ³⁴Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain
Background/Purpose: IgG4-related disease (IgG4-RD) is a rare immune-mediated condition characterized by fibro-sclerosing inflammation, elevated serum and tissue IgG4 levels, and heterogeneous clinical manifestations. Several classification…
Abstract Number: 0165 • ACR Convergence 2025
Per-Protocol Analysis of the Effectiveness of GLP1 Agonists Against SGLT2 Inhibitors on Osteoarthritis Outcomes
Nene Ukonu¹, David Felson², Michael LaValley³ and S. Reza Jafarzadeh⁴, ¹Boston University School of Public Health, Boston, MA, ²Boston University, Boston, MA, ³Boston University School of Public Health, Arlington, MA, ⁴Boston University Chobanian & Avedisian School of Medicine, Boston, MA
Background/Purpose: Anti-diabetic medications often have effects on other conditions. GLP1 agonists (GLP1a) have shown protective effects on OA outcomes in trials and short-term trial emulations,…
Abstract Number: 0200 • ACR Convergence 2025
Severe infections and malignancies in patients with cranial and extracranial giant cell arteritis treated with tocilizumab. National multicenter study of 471 patients of clinical practice
Adrian Martin-Gutierrez¹, Javier Loricera², Vicente Aldasoro Cáceres³, Olga Maiz⁴, Eugenio de Miguel⁵, Eva Galíndez Agirregoikoa⁶, Ivan Ferraz Amaro⁷, Santos Castañeda⁸ and Ricardo Blanco⁹, ¹Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Renedo de Piélagos, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ³Hospital Universitario de Navarra, Pamplona, Spain, ⁴Hospital Universitario de Donosti, Donostia, Spain, ⁵Hospital Universitario La Paz, Madrid, Spain, ⁶BASURTO UNIVERSITY HOSPITAL, BILBAO, Spain, ⁷Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ⁸Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, ⁹Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain
Background/Purpose: Infections and malignancies are two of the most feared side effects of biologic therapies. Giant cell arteritis (GCA) is a vasculitis which affects older…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].